Novel Radiotracer PET-CT Imaging: A Noninvasive Means to Characterize Small Renal Masses

PET-CT imaging using [⁸⁹Zr]Zr-girentuximab, a radiolabeled monoclonal antibody that binds to an antigen expressed on tumor cells, was highly sensitive and specific for detecting clear-cell renal carcinoma.

Detection of small renal masses (i.e., ≤4 cm) is increasing, partly due to widespread use of abdominal computed tomography (CT) and magnetic resonance imaging (MRI) and an aging population. Current imaging technologies cannot distinguish between benign and malignant lesions.

Investigators conducted an industry-sponsored, open-label, multicenter phase 3 trial of positron-emission tomography (PET)–CT imaging using [⁸⁹Zr]Zr-girentuximab, a chimeric monoclonal antibody directed against an antigen associated with renal cell carcinoma, to determine its sensitivity and specificity in detecting clear-cell renal cell carcinoma. Histopathological confirmation by pathologists blinded to patient information served as the gold standard. A single dose of …

Reviewing Author

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Novel Radiotracer PET-CT Imaging: A Noninvasive Means to Characterize Small Renal Masses

Topics

Reviewing Author